Log in

NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

$58.11
-3.12 (-5.10 %)
(As of 03/29/2020 01:23 PM ET)
Today's Range
$56.95
Now: $58.11
$60.81
50-Day Range
$48.11
MA: $58.86
$67.97
52-Week Range
$43.29
Now: $58.11
$102.98
Volume824,601 shs
Average Volume1.01 million shs
Market Capitalization$3.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Blueprint Medicines logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$66.51 million
Book Value$9.44 per share

Profitability

Net Income$-347,690,000.00
Net Margins-522.75%

Miscellaneous

Employees217
Market Cap$3.14 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.


Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

How has Blueprint Medicines' stock been impacted by COVID-19 (Coronavirus)?

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BPMC stock has increased by 10.9% and is now trading at $58.11. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Blueprint Medicines?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Blueprint Medicines.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Blueprint Medicines.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) posted its quarterly earnings data on Thursday, February, 13th. The biotechnology company reported ($1.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to analyst estimates of $26 million. Blueprint Medicines had a negative net margin of 522.75% and a negative return on equity of 72.52%. The business's revenue was up 4888.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.83) EPS. View Blueprint Medicines' earnings history.

What price target have analysts set for BPMC?

13 Wall Street analysts have issued 12 month target prices for Blueprint Medicines' shares. Their forecasts range from $70.00 to $125.00. On average, they anticipate Blueprint Medicines' stock price to reach $105.75 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price. View analysts' price targets for Blueprint Medicines.

Has Blueprint Medicines been receiving favorable news coverage?

Media headlines about BPMC stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Blueprint Medicines earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBlueprint Medicines.

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a increase in short interest in February. As of February 28th, there was short interest totaling 2,920,000 shares, an increase of 8.6% from the February 13th total of 2,690,000 shares. Based on an average daily trading volume, of 747,600 shares, the days-to-cover ratio is currently 3.9 days. Approximately 7.0% of the shares of the company are sold short. View Blueprint Medicines' Current Options Chain.

Who are some of Blueprint Medicines' key competitors?

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Micron Technology (MU), Crispr Therapeutics (CRSP), Nektar Therapeutics (NKTR), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Agile Therapeutics (AGRX) and Intercept Pharmaceuticals (ICPT).

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the following people:
  • Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
  • Mr. Michael Landsittel, Chief Financial Officer (Age 47)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Alliancebernstein L.P. (2.08%), Norges Bank (1.85%) and Westfield Capital Management Co. LP (1.57%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View institutional ownership trends for Blueprint Medicines.

Which institutional investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Macquarie Group Ltd., Macquarie Group Ltd., Victory Capital Management Inc., and Westfield Capital Management Co. LP. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, and Nicholas Lydon. View insider buying and selling activity for Blueprint Medicines.

Which institutional investors are buying Blueprint Medicines stock?

BPMC stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Alliancebernstein L.P., and Jane Street Group LLC. View insider buying and selling activity for Blueprint Medicines.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $58.11.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $3.14 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe. View additional information about Blueprint Medicines.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]


MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  426 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  721
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: How a Put Option Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel